Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BTMD 
biote Corp (BTMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: BTMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.51
1 Year Target Price $4.51
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.28% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 122.50M USD | Price to earnings Ratio 3.24 | 1Y Target Price 4.51 |
Price to earnings Ratio 3.24 | 1Y Target Price 4.51 | ||
Volume (30-day avg) 6 | Beta 1.15 | 52 Weeks Range 2.31 - 6.90 | Updated Date 12/2/2025 |
52 Weeks Range 2.31 - 6.90 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When - | Estimate 0.1325 | Actual 0.1777 |
Profitability
Profit Margin 14.72% | Operating Margin (TTM) 18.12% |
Management Effectiveness
Return on Assets (TTM) 21.95% | Return on Equity (TTM) - |
Valuation
Trailing PE 3.24 | Forward PE 6.57 | Enterprise Value 156901257 | Price to Sales(TTM) 0.63 |
Enterprise Value 156901257 | Price to Sales(TTM) 0.63 | ||
Enterprise Value to Revenue 0.8 | Enterprise Value to EBITDA 3.39 | Shares Outstanding 30680960 | Shares Floating 16315256 |
Shares Outstanding 30680960 | Shares Floating 16315256 | ||
Percent Insiders 13.35 | Percent Institutions 63.13 |
Upturn AI SWOT
biote Corp
Company Overview
History and Background
biote Corp, founded in 2011, focuses on hormone optimization through subcutaneous hormone pellet therapy. It has expanded through strategic partnerships and acquisitions, establishing a national presence.
Core Business Areas
- Hormone Pellet Therapy: biote Corp's primary focus is on providing bioidentical hormone replacement therapy (BHRT) using subcutaneous hormone pellets for both men and women experiencing hormone imbalances. Includes consultations, lab tests, and pellet insertion procedures.
- Nutraceuticals: biote Corp also offers a range of nutraceutical supplements designed to support hormone optimization and overall health.
- Practice Management: Provides support, including training and educational programs, for medical practitioners interested in offering bioidentical hormone replacement therapy (BHRT).
Leadership and Structure
The leadership team includes Terry Weber (CEO) and Gary S. Donovitz, M.D. (Founder). The company structure involves a network of certified providers and a corporate support system.
Top Products and Market Share
Key Offerings
- biote Method: This encompasses the entire hormone optimization program, including consultations, lab testing, and hormone pellet insertion. Market share data is not explicitly public, but the company is a leader in BHRT. Competitors include SottoPelle, EvexiPEL, and Defy Medical.
- Nutraceuticals: A range of supplements designed to support hormone optimization, including ADK 10, DIM SGS+, and i-FACTOR. Revenue from nutraceuticals contributes to the overall revenue stream. Competitors include Thorne Research, Metagenics, and Designs for Health.
Market Dynamics
Industry Overview
The hormone replacement therapy market is growing, driven by an aging population and increased awareness of hormone imbalances. The market is competitive, with various delivery methods and providers.
Positioning
biote Corp positions itself as a leader in BHRT using subcutaneous hormone pellets, emphasizing its comprehensive method and network of certified providers.
Total Addressable Market (TAM)
The global hormone replacement therapy market is projected to reach $22.8 billion by 2030. biote Corp's position with respect to this TAM is to capture a significant share of the BHRT segment through its expanding network and established brand.
Upturn SWOT Analysis
Strengths
- Established brand in BHRT
- Network of certified providers
- Proprietary hormone pellet formulation
- Comprehensive training and support programs
Weaknesses
- Reliance on a specific delivery method (pellets)
- Potential regulatory scrutiny related to hormone therapy
- Limited geographic reach outside the United States
- High initial costs for patients
Opportunities
- Expansion into new geographic markets
- Development of new products and services
- Increased awareness of hormone imbalances
- Strategic partnerships with other healthcare providers
Threats
- Competition from other hormone replacement therapies
- Negative publicity or research findings
- Changes in regulations governing hormone therapy
- Economic downturn affecting consumer spending on elective procedures
Competitors and Market Share
Key Competitors
- SottoPelle (Private)
- EvexiPEL (Private)
- Defy Medical (Private)
Competitive Landscape
biote Corp has a strong brand and network but faces competition from other BHRT providers. Its advantages include its proprietary hormone pellet formulation and comprehensive training programs. Disadvantages include reliance on a specific delivery method.
Major Acquisitions
Skytale Group
- Year: 2024
- Acquisition Price (USD millions): 45
- Strategic Rationale: To enhance practice optimization and consulting services for its providers, driving further adoption and success with the biote Method.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is demonstrated by an increasing provider network and revenue growth from hormone pellet therapy and nutraceutical sales.
Future Projections: Future growth projections are often based on analyst estimates, which take into account market trends, competition, and company strategy. Projected growth rates are available in analyst reports.
Recent Initiatives: Recent strategic initiatives include expanding the provider network, introducing new nutraceutical products, and enhancing training programs for providers.
Summary
biote Corp is a prominent player in the growing BHRT market, particularly through its specialized pellet therapy. The company's strengths lie in its established brand and extensive provider network. Its weaknesses include a reliance on pellet delivery and regulatory risks. It must capitalize on market expansion and product development while monitoring competition and regulatory changes.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
- Company Website
Disclaimers:
This analysis is based on available public information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About biote Corp
Exchange NASDAQ | Headquaters Irving, TX, United States | ||
IPO Launch date 2021-04-28 | CEO & Director Mr. Bret Christensen | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 217 | Website https://www.biote.com |
Full time employees 217 | Website https://www.biote.com | ||
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.